1. Home
  2. HOVR vs GANX Comparison

HOVR vs GANX Comparison

Compare HOVR & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Horizon Aircraft Ltd.

HOVR

New Horizon Aircraft Ltd.

HOLD

Current Price

$1.74

Market Cap

80.6M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.79

Market Cap

76.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOVR
GANX
Founded
2013
2017
Country
Canada
United States
Employees
30
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.6M
76.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
HOVR
GANX
Price
$1.74
$1.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$10.33
$7.50
AVG Volume (30 Days)
1.1M
684.8K
Earning Date
04-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.46
EPS
N/A
N/A
Revenue
N/A
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.16
$1.41
52 Week High
$4.18
$4.34

Technical Indicators

Market Signals
Indicator
HOVR
GANX
Relative Strength Index (RSI) 36.24 47.40
Support Level $1.72 $1.66
Resistance Level $1.91 $2.15
Average True Range (ATR) 0.13 0.14
MACD -0.02 -0.00
Stochastic Oscillator 11.97 19.64

Price Performance

Historical Comparison
HOVR
GANX

About HOVR New Horizon Aircraft Ltd.

New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: